학술논문
122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2023 20 Supplement
Subject
Language
ISSN
2590-0188